Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 287-294

  Milanetti, F ^a   Germano, V ^a   Nisini, R ^b   Donatelli, I ^b   Di Martino, A ^b   Facchini, M ^b   Ferlito, C ^a   Cappella, A ^a   Crialesi, D ^a   Caporuscio, S ^a   Biselli, R ^c   Rossi, F ^a   Salemi, S ^a   D'Amelio, R ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c National Health Service   (Italy)

Author keywords

Rheumatoid arthritis; T cells; Vaccination

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; IMMUNOLOGICAL ADJUVANT; INFLIXIMAB; INFLUENZA VACCINE; MIFAMURTIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS ANTIGEN;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASTHENIA; BIOLOGICAL THERAPY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; INJECTION SITE REACTION; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEASONAL INFLUENZA; SEROCONVERSION; SKIN REDNESS; SWELLING; T LYMPHOCYTE; VIRUS STRAIN;

RHEUMATOID ARTHRITIS; T CELLS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCONJUGATES; INFLUENZA VACCINES; INFLUENZA, HUMAN; ITALY; MALE; MIDDLE AGED; PANDEMICS; POLYSORBATES; SEASONS; SQUALENE; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904240867     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12292     Document Type: Article

References (57)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287-2293.
2. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxf) 2013; 52:53-61.
3. Salemi S, D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol 2010; 29:270-314.
4. Blank P, Schwenkglenks M, Szucs TD. The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly. Hum Vaccin Immunother 2012; 8:328-335.
5. Bridges MJ, Coady D, Kelly CA, Hamilton J, Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:685.
6. Fahy WA, Farnworth E, Yeldrem KP, Melling GS, Grennan DM. Pneumococcal and influenza vaccination in patients with rheumatic conditions and receiving DMARD therapy. Rheumatology (Oxf) 2006; 45:912-913.
7. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:837-838.
8. Sowden E, Mitchell W. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord 2007; 8:58.
9. Arnett FC, Edworthy SM, Bloch DA etal. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
10. World Health Organization. Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf (accessed 23 August 2012).
11. Belshe RB, Newman FK, Cannon J etal. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-2294.
12. Salemi S, Picchianti-Diamanti A, Germano V etal. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNF-α blockers: safety and immunogenicity. Clin Immunol 2010; 134:113-120.
13. Tsai TF. MF59 adjuvanted seasonal and pandemic influenza vaccines. Yakuga Zasshi 2011; 131:1733-1741.
14. Thomson CA, Wang Y, Jackson LM etal. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front Immunol 2012; 3:art 87, 1-19.
15. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009; 27:6959-6965.
16. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011; 343:D5956.
17. Gabay C, Bel M, Combescure C etal., H1N1 Study Group. Impact of synthetic and biologic disease-modifying anti-rheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63:1486-1496.
18. Elkayam O, Amir S, Mendelson E etal. Efficacy and safety of vaccination against pandemic 2009 influenza A H1N1 virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63:1062-1067.
19. Adler S, Krivine A, Weix J etal. Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study. Rheumatology (Oxf) 2012; 51:695-700.
20. Urowitz MB, Anton A, Ibanez D, Gladman DD. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63:1517-1520.
21. Hancock K, Veguilla V, Lu X etal. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-1952.
22. Gasparini R, Schioppa F, Lattanzi M etal. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria TM) in adult and elderly subjects. Int J Clin Pract 2010; 64:432-438.
23. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLOS ONE 2011; 6:e16496.
24. Lemaitre M, Leruez-Ville M, De Lamballerie XN etal. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. Clin Microbiol Infect 2011; 17:732-737.
25. Yin JK, Chow MY, Khandaker G etal. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. Vaccine 2012; 30:3209-3222.
26. Zuccotti GV, Pariani E, Scaramuzza A etal. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Diabet Med 2011; 28:1530-1536.
27. Peeters M, Regner S, Vaman T, Devaster JM, Rombo L. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials. Vaccine 2012; 30:6483-6491.
28. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375:49-55.
29. Saad CGS, Borba EF, Aikawa NE, Silva C. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011; 70:1068-1107.
30. Ribeiro AC, Guedes LK, Moraes JC etal. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011; 70:2144-2147.
31. Iwamoto M, Homma S, Onishi S etal. Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 2012; 32:3691-3694.
32. Ribeiro AC, Laurindo IM, Guedes LK etal. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65:476-480.
33. França IL, Ribeiro AC, Aikawa NE etal. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxf) 2012; 51:2091-2098.
34. Song JY, Cheong HJ, Seo YB etal. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. Clin Vaccine Immunol 2012; 19:638-641.
35. Khurana S, Chearwae W, Castellino F etal. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2:15ra5.
36. Khurana S, Verma N, Yewdell JW etal. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48.
37. Schmidt T, Dirks J, Enders M etal. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. Eur J Immunol 2012; 42:1755-1766.
38. Igari H, Watanabe A, Segawa S etal. Immunogenicity of a monovalent pandemic influenza A H1N1 virus vaccine with or without prior seasonal influenza vaccine administration. Clin Vaccine Immunol 2012; 19:1690-1692.
39. Beyer WEP, Palache AM, Sprenger MJW etal. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1996; 14:1331-1339.
40. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxf) 2007; 46:608-611.
41. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34:272-279.
42. Sasaki S, He XS, Holmes TH etal. Influence of prior influenza vaccination on antibody and B-cell responses. PLOS ONE 2008; 3:e2975.
43. Holvast A, Huckriede A, Wilschut J etal. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65:913-918.
44. Huijskens E, Rossen J, Mulder P etal. Immunogenicity, boostability and sustainability of the immune response after vaccination against influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011; 18:1401-1405.
45. Beye WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination; a meta-analysis of serologic and field studies. Arch Intern Med 1999; 159:182-188.
46. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997; 15:1114-1122.
47. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979; 1:33-35.
48. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005; 11 (Suppl. 4): S54-62.
49. Ohmit SE, Thompson MG, Petrie JG etal. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-327.
50. McElhaney JE, Ewen C, Zhou X etal. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418-2425.
51. Arad U, Tzadok S, Amir S etal. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29:1643-1648.
52. Holvast A, de Haan A, van Assen S etal. Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis. Ann Rheum Dis 2010; 69:924-927.
53. Setti M, Fenoglio D, Ansaldi F etal. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009; 27:3367-3372.
54. Holvast A, van Assen S, de Haan A etal. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009; 60:2438-2447.
55. Faenzi E, Zedda L, Bardelli M etal. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine 2012; 30:4086-4094.
56. Kobie JJ, Zheng B, Bryk P etal. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-TNF. Arthritis Res Ther 2011; 13:R209.
57. Salemi S, Germano V, Picchianti Diamanti A, D'Amelio R. Role of antibody-secreting cells as early biomarkers of immune response to influenza vaccination in rheumatoid arthritis patients treated with anti-TNF agents. Int J Clin Rheumatol 2012; 7:155-158.